Search clinical trials for: IDP-123 Lotion

Total 97341 results

Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Atopic Dermatitis

United States
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Acne

United States
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel

Acne

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

Acne Vulgaris

United States
Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris; ARS (Association... and other collaborators

Completed

Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls (DOSERAL)

Amyotrophic Lateral Sclerosis

France
Valeant Pharmaceuticals

Unknown

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
InQpharm Group

Completed

Benefit and Tolerability of IQP-AE-103 in Weight Loss

Obesity | Overweight

Germany
Ake Norberg

Completed

A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA

Healthy | SIRS

Sweden
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
InnoCare Pharma Inc.

Active, not recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Pfizer

Terminated

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Cachexia

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-323 in Healthy Subjects

RSV Infection

United States
InQpharm Group

Withdrawn

Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

Fatigue

Germany
Institute for Neurodegenerative Disorders
United States Department of Defense; University of Oklahoma

Completed

Development of Cognitive Assessment Tools in Parkinson Disease (ANAM)

Parkinson Disease

United States
Perrigo CSCI
Analyze & Realize

Completed

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

Obesity | Overweight

Germany
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
VA Puget Sound Health Care System
Dr. Gregory Merrick; Theragenics Corporation

Unknown

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Prostate Cancer

United States
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Recruiting

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

RSV Infection

United Kingdom
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration

Diabetes Mellitus
Bausch Health Americas, Inc.

Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Acne Vulgaris

United States, Belgium, Canada
ModernaTX, Inc.

Completed

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

SARS-CoV-2

United States
MegaPro Biomedical Co. Ltd.

Completed

The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma

Magnetic Resonance Imaging

Taiwan
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
ModernaTX, Inc.

Completed

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

SARS-CoV-2

United States
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Institute for Neurodegenerative Disorders

Terminated

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Prostate Cancer

United States

3

Subscribe